Published in:
Open Access 01-12-2012 | Research article
Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data
Published in: BMC Infectious Diseases | Issue 1/2012
Login to get accessAbstract
Background
Analysis of US claims data from April 2010 to June 2011 estimated that 39% of the 13-valent pneumococcal conjugate vaccine (PCV13) catch-up eligible cohort would ever receive the catch-up vaccination; a previous analysis assumed 87%.
Methods
This updated figure was applied to a previously published 10-year Markov model while holding all other inputs constant.
Results
Our model estimated that the catch-up program as currently implemented is estimated to prevent an additional 1.7 million cases of disease in children aged ≤59 months over a 10-year period, compared with routine PCV13 vaccination with no catch-up program.
Conclusions
Because 39% catch-up uptake is less than the level of completion of the 4-dose primary PCV13 series, vaccine-preventable cases of pneumococcal disease and related deaths could be decreased further with additional uptake of catch-up vaccination in the catch-up eligible cohort.